-
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish
Tuesday, April 15, 2025 - 11:57am | 312Read More...A physician survey for Neurocrine Biosciences Inc's (NASDAQ:NBIX) Crenessity suggests "strong uptake across all patient segments," according to Needham. The Neurocrine Biosciences Analyst: Analyst Ami Fadia upgraded the rating from Hold to Buy, while raising the price target to $138. The...
-
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
Wednesday, September 28, 2022 - 12:10pm | 768Read More...Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...
-
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst
Thursday, September 23, 2021 - 5:04pm | 368Read More...It's been about four months since Biogen, Inc. (NASDAQ: BIIB) received approval for its controversial Alzheimer's treatment Aduhelm. The initial broad approval was later narrowed by the FDA. The "Aduhelm opportunity" for the biopharma is underappreciated, an analyst said Thursday...
-
Why Amarin Shares Are Plunging Wednesday
Wednesday, September 2, 2020 - 2:32pm | 414Read More...Amarin Corporation plc (NASDAQ: AMRN) shares were plummeting on above-average volume as an appeal hearing on the Vascepa fish oil capsule patent gets underway. What Happened: Amarin appealed against a late March ruling that its Vascepa patents were invalid. The invalidation of the patents...
-
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
Wednesday, June 17, 2020 - 11:52am | 715Read More...Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa. The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price...
-
Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement
Friday, May 22, 2020 - 1:15pm | 557Read More...Amarin Corporation plc (NASDAQ: AMRN) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a third-party pilot trial of its Vascepa in COVID-19, were giving back the gains Friday. First Vascepa Generic Greenlighted The negative sentiment...
-
Leerink: Improving Fundamentals Drive Teva Upgrade
Monday, October 1, 2018 - 2:01pm | 498Read More...TEVA Pharmaceutical Industries (NASDAQ: TEVA)'s fundamentals have substantially improved over the last few months, giving the stock a more balanced risk-reward profile, according to Leerink. The Analyst Leerink analyst Ami Fadia upgraded TEVA Pharmaceutical from Underperform to Market...
-
Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms
Thursday, April 12, 2018 - 12:26pm | 390Read More...Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...
-
UBS Steps To Sidelines on Depomed, Citing Limited Upside; Stock Sinks ~6%
Thursday, July 7, 2016 - 10:28am | 300Read More...Depomed Inc (NASDAQ: DEPO) shares have surged about 25 percent since mid-February, and UBS’ Ami Fadia believes there is limited upside going forward. Fadia downgraded the rating on the company from Buy to Neutral, with a price target of $20. Limited Upside The analyst believes there could be...
-
UBS Starts Depomed At Buy, Says Nucynta Has More Potential Than Market Thinks
Tuesday, February 9, 2016 - 11:51am | 265Read More...The share price of Depomed Inc (NASDAQ: DEPO) has appreciated 2.27 percent over the last one month, while rising almost 4 percent in morning trade on February 9. Ami Fadia of UBS has initiated coverage of the company with a Buy rating and price target of $22. Feedback from physicians...
-
UBS Maintains Buy Rating On Pfizer Inc. (PFE)
Thursday, April 1, 2010 - 12:34pm | 112Read More...Analysts Marc Goodman and Ami Fadia at UBS have released an update on Pfizer Inc. (NYSE: PFE). UBS recently attended an investor dinner with Pfizer’s CFO and IR. The key takeaways from the meeting, according to analysts, are the company’s commitment to 2012 guidance and its willingness to cut...
